Medtronic PLC beat earnings as well as revenue estimates for the fiscal third quarter.
The healthcare device company’s earnings of $1.29 per cents per share for the quarter was higher five cents compared to than analysts’ estimates. Revenue of $2.12 billion edged past analysts’ expectations of $2.08 billion. Its minimally invasive therapies business, which makes surgical instruments and endoscopy products, was a major contributor to the sales performance.
Medtronic projects its full-year earnings to be in the range of $5.14 and $5.16 per share – that’s higher compared to its previous predicted range of $5.10 to $5.15 per share. Analysts are expecting earnings of $5.12 per share.
The company also revised its 2019 organic revenue growth forecast range upwards to 5.25% - 5.5 %, albeit with a caveat that a strong dollar would affect its full-year revenue by about $425 million to $475 million.
Omar Ishrak, Medtronic chairman and chief executive officer indicated that the company’s business diversification was an advantage in generating the strong sales figures. "Revenue outperformance in our Minimally Invasive Therapies and Restorative Therapies Groups, as well as broad strength across Emerging Markets, helped to offset certain market-specific headwinds we faced during the quarter, reflecting the full benefits of our diversification", Ishrak said.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .
MDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 245 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on May 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MDT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MDT turned negative on May 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
MDT moved below its 50-day moving average on May 21, 2025 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for MDT moved below the 200-day moving average on May 21, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.231) is normal, around the industry mean (24.191). P/E Ratio (27.625) is within average values for comparable stocks, (79.080). Projected Growth (PEG Ratio) (1.648) is also within normal values, averaging (5.667). Dividend Yield (0.032) settles around the average of (0.018) among similar stocks. P/S Ratio (3.588) is also within normal values, averaging (42.393).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of medical technology services
Industry MedicalSpecialties